TY - JOUR
T1 - Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials
AU - Bayle, Arnaud
AU - Belcaid, Laila
AU - Cousin, Sophie
AU - Trin, Kilian
AU - Alame, Melissa
AU - Rouleau, Etienne
AU - Soubeyran, Isabelle
AU - Lacroix, Ludovic
AU - Blouin, Laura
AU - Vasseur, Damien
AU - Crombe, Amandine
AU - Mathoulin-Pelissier, Simone
AU - Soria, Jean Charles
AU - Bellera, Carine
AU - Italiano, Antoine
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.
AB - Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.
UR - http://www.scopus.com/inward/record.url?scp=85206091618&partnerID=8YFLogxK
U2 - 10.1038/s41698-024-00685-9
DO - 10.1038/s41698-024-00685-9
M3 - Article
AN - SCOPUS:85206091618
SN - 2397-768X
VL - 8
JO - npj Precision Oncology
JF - npj Precision Oncology
IS - 1
M1 - 227
ER -